




**December 2016**  
**Enrolling Physicians for November 2016**

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits	Tissue Procurement	Cancer Care Delivery Res.
Dr. Biggers (Cox)					2	
Dr. Bonebrake (Cox)		0.5125		0.5125	4	
Dr. Ding (Cox)		0.2625	0.0125	0.2750		1
Dr. Carlson (Mercy Spfld)	1	1.5250	.25	1.7750	1	
Dr. Donegan (Mercy St. Louis)	2	2.1	.25	2.35		
Dr. Ellis (OHA)		0.2625		0.2625		
Dr. Gillett (OHA)	1	1.0375	0.0125	1.05		1
Dr. Goodwin (Mercy Spfld)			0.0125	0.0125		1
Dr. Pinheiro (Mercy Spfld)					3	
Dr. Snider (Mercy Spfld)	1	1.025	0.2750	1.3		1
Dr. Tiriveedhi (MercySpfld)			0.0125	0.0125		2
Dr. Tummala (Mercy Spfld)			0.0250	0.0250		1
<b>TOTALS</b>	<b>5</b>	<b>6.725</b>	<b>0.85</b>	<b>7.575</b>	<b>10</b>	<b>7</b>

Seven patients were enrolled to our open CCDR study and ten tissue plus blood specimens were obtained in November. Four months into our current grant year we are at 56% in meeting our NCI credit goal of 160 for this grant year. We need to be at 53.33credits and we have earned 29.7125. Please make every effort to enroll patients to trials which they qualify. The below chart shows the percentage all NCORPs achieved during the first two years of the NCORP program. CRO achieved 72% (GY 2014-15 = 81% and GY 2015-2016 = 62%) of their NCI goal during this period. This gives us an idea of how we compare with other NCORPs during the first two years of the NCORP grant.

**NCORP Achievement of Accrual Credits**

**Year 1 and 2 Combined**



## **CRO TV & Radio 30-second Ads**

CRO's 30 sec TV ads began airing on November 21, 2016 with television stations KYTV (3/NBC), KOLR (10/CBS) and KSPR (33/ABC). Our 30 sec radio spots with KGBX-FM, KTTS-FM and KSGF-FM in Springfield; KHBZ-FM in Branson, Missouri and KKLB-FM in Monett, Missouri also began airing at the same time. Our marketing campaign will run from November 21, 2016 through February 20, 2017. Our goal is to educate our community regarding clinical trials in hopes of increasing numbers of patients saying yes to clinical trial participation. Special thanks to Dr. Abe Abdalla, Dr. Jay Carlson and nurse practitioner Dorothy Harsen, for their support in developing our ads.

## **CCDR Opens to all Components**

Effective November 1, 2016, participation in Cancer Care Delivery Research (CCDR) studies will no longer be limited to components and sub-components named in the original NCORP Community Site grant application. Any component or sub-component of an NCORP site rostered with a CTEP ID is eligible for participation in approved CCDR studies. No additional funding will be available; all CCDR work must be completed using the existing CCDR-restricted funds. As is currently the case, CCDR studies are open to the NCORP network. Dr. Wortia McCaskill Stevens, Chief Community Oncology and Prevention Trials Research Group and NCORP Director wrote, "We hope this facilitates high quality CCDR by providing study chairs and site PIs the opportunity to match study needs to component and sub-component interest and capacity."

## **COMET COMMunication and Education in Tumor Profiling (EAQ152)**

This is a randomized study of Pre-test genetic education verses usual care in tumor profiling for advanced cancer and a pilot study of remote genetic counseling for participants with potential germline mutations identified on tumor profiling. This research trial studies how well pre-test genetic education and remote genetic counseling works in communicating tumor profiling results to patients with advanced cancer. Web-based genetic education before receiving tumor profiling results and remote genetic counseling for patients with potential germline mutations may increase genetic knowledge and reduce distress for patients with advanced cancer. The study is limited to patients enrolled in the MATCH (EAY-133) trial who have not yet received their results. 400 patients are being sought for the trial.

## **ACTIVATION OF CIRB Protocols:**

**SWOG S1512** A Phase II And Pilot Trial Of Pd-1 Blockade With Mk-3475 (Pembrolizumab) In Patients With Resectable Or Unresectable Desmoplastic Melanoma (Dm)

**NRG-GI002** A Phase II Clinical Trial Platform Of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) In Rectal Cancer

**ALLIANCE A011502** A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin Adjuvant Therapy For Node Positive Her2 Negative Breast Cancer: The Abc Trial – Pre-activation status

## **Re-ACTIVATION OF CIRB Protocols:**

**Alliance A091202** A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unresectable Myxoid Liposarcoma Reactivated effective 10/01/2016

## **CIRB Studies Closed:**

**AEWS1221** Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma - Temporary Closure to accrual effective 10/12/2016

**ECOG-ACRIN EAY131 Sub-study N** Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC.- Suspended to enrollment effective 11/16/2016

**SWOG S1505** A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma - Temporary Closure effective 11/1/2016